focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS: Broker Ratings Changes Drive FTSE 100 Movers

Mon, 23rd Mar 2015 11:22

LONDON (Alliance News) - The following stocks are amongst the biggest risers and fallers within the main London indices midday Monday.
-------
FTSE 100 WINNERS
-------
Standard Chartered, up 5.1%. JP Morgan has raised the emerging markets bank to Overweight from Neutral.
-------
FTSE 100 LOSERS
-------
Carnival, down 2.8%. Deutsche Bank has downgraded the cruise operator to Hold from Buy.

Meggitt, down 1.9%. Bernstein has downgraded the engineer of components for the aerospace, defence and energy markets to Market-Perform from Outperform, according to traders.
-------
FTSE 250 WINNERS
-------
Centamin, up 14%. The Egypt-focused gold miner reported a sharp drop in pretax profit for 2014 as the falling gold price offset a rise in production, but the company still declared a dividend for the year. Centamin said its pretax profit for the year was USD81.6 million, less than half the USD184 million it posted a year earlier. Revenue dropped to USD472.6 million from USD503.8 million. However, the company proposed a final dividend of 1.99 US cents per share, giving it a total payout of 2.86 cents per share for the year. Centamin paid no dividend in 2013.

FirstGroup, up 3.8%. The transport operator said it had retained the First Great Western rail franchise in the UK until at least April 2019, and pledged to add new and updated trains, faster services, more direct trains to Devon and Cornwall and improvements to infrastructure. The company said it will continue the franchise until April 1, 2019, and the deal could be extended for a further year at the UK government's discretion. It has already been running the franchise since 2006.

Vedanta Resources, up 2.4%. JP Morgan has raised the miner's price target to 520.00 pence from 450.00p. The stock currently trades at 537.50p.

Pennon Group, up 1.8%. The water utility and waste management company said trading remains in line with expectations for its financial year to the end of March, with its South West Water business performing well and its Viridor waste management division making progress, leading the company to reiterate its dividend growth plans. It said it is well placed to generate increasing operating cashflows over the 2015-2020 regulatory period and, as a result, intends to continue with its current dividend policy of year-on-year growth of 4% above UK retail prices index inflation over that period.
-------
AIM ALL-SHARE WINNERS
-------
Silence Therapeutics, up 22%. The company said it had seen an "excellent outcome" in its Phase IIa trial of compound Atu027 in pancreatic cancer. The primary objective of the trial was to assess the safety and pharmacokinetics of the compound, and the second objective was to evaluate its efficacy including progression free survival.

Verona Pharma, up 21%. The company said it has seen "very encouraging" initial interim results from its ongoing phase I/II clinical trial with a new nebulised formulation of its RPL554 compound. Results from the first part of the study showed the drug was well tolerated across all doses tested, and no maximum tolerated dose could be defined. It noted that there were no changes in the subject's cardiovascular parameters, and a complete absence of nausea or vomiting at all doses.

Metal Tiger, up 19%. The company said it has now implemented its divisional restructuring and is in the position to self-finance its activities. The company said its two new investment divisions, Direct Equities and Direct Projects, are now embedded and fully operational. It had said in Late January it was to create the new structure as part of an updated strategic approach.

Premaitha Health, up 16%. The company said it has been awarded a three-year contract to provide its non-invasive prenatal test, known as IONA, to St George's University Hospitals NHS Foundation Trust. The test is currently the subject of a patent infringement suit filed by NASDAQ listed Illumina Inc last Monday. The contract was awarded following a competitive tender process, and St George's Hospital in South West London will be the first National Health Service facility to offer non-invasive prenatal testing in-house.
-------
AIM ALL-SHARE LOSERS
-------
Clean Air Power, off 31%. The company reported a sharp drop in revenue and an increase in cash consumption in 2014 and warned that 2015 would also be challenging as it seeks fresh funding to shore up an uncertain financial future. Clean Air Power said it faces significant doubt over whether it can continue in business unless it secures additional funding. It said it now has limited means to further cut costs, and is now seeking fresh funding through either a second major deal with a manufacturer, which would boost cash flow, or "alternative sources of funding". It said talks are ongoing with a number of manufacturers.

SpaceandPeople, down 15%. The marketing company said its pretax profit dropped in 2014 as a rise in its cost of sales outpaced revenue growth and said it would slash its dividend. It said its pretax profit fell to GBP596,000 from GBP1.8 million a year earlier.

Egdon Resources, down 10%. Europa Oil & Gas and Egdon Resources said they have plugged and abandoned the Kiln Lane-1 exploration well in the East Midlands of England and will return the site to farmland after drilling encountered sandstones with too much water.
-------

By Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
7 Mar 2019 11:28

DIRECTOR DEALINGS: Verona Pharma Chair David Ebsworth Buys Shares

LONDON (Alliance News) - Clinical-stage biopharmaceutical company Verona Pharma PLC said on Thursday Chair David Ebsworth bought 26,300 shares for 56.30 pence each on Wednesday.Following in

Read more
4 Mar 2019 13:35

Monday broker round-up

(Sharecast News) - RSA Insurance Group: JP Morgan downgrades to neutral with a target price of 610p.

Read more
4 Mar 2019 10:12

Verona Pharma Reports Positive Data From Lung Disease Treatment Trial

LONDON (Alliance News) - Shares in Verona Pharma PLC rose on Monday following positive data from part of a Phase Two clinical trial of a dry powder inhaler formulation of Verona's ensifentrine

Read more
14 Jan 2019 10:23

WINNERS & LOSERS SUMMARY: JD Sports Rises After Strong Christmas

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - LOSERS----------Paddy Power

Read more
14 Jan 2019 09:47

Verona Pharma's Ensifentrine COPD Study Does Not Meet Primary Endpoint

LONDON (Alliance News) - Verona Pharma PLC on Monday said its phase two clinical trial of nebulized Ensifentrine did not meet its primary endpoint but did perform better than placebo.Shares

Read more
14 Jan 2019 08:48

Verona Pharma shares plunge on latest drug trial results

(Sharecast News) - Verona Pharma shares were well into the red on Monday, after the clinical-stage biopharmaceutical company announced top-line data from its latest trial of RPL554, failing to reach its primary endpoint.

Read more
9 Jan 2019 15:44

Verona Pharma granted WHO approval for Ensifentrine name

(Sharecast News) - Clinical stage biopharmaceutical outfit Verona Pharma has been granted approval of the name Ensifentrine for its first-in-class, inhaled, dual inhibitor drug candidate RPL554 by the World Health Organisation.

Read more
17 Dec 2018 14:22

Verona Pharma initiates Phase 2 study of RPL554

(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma announced the initiation of a Phase 2 clinical trial to evaluate the pharmacokinetic (PK) profile, efficacy and safety of a dry powder inhaler (DPI) formulation of 'RPL554', in patients with moderate to severe chronic obstructive pulmonary disease (COPD), on Monday.

Read more
6 Nov 2018 11:56

Verona Pharma Third-Quarter Loss Narrows On Finance Income

LONDON (Alliance News) - Verona Pharma PLC on Tuesday said its loss narrowed by two thirds in the third quarter of 2018 on increased finance income and reduced costs as it initiated a phase two of

Read more
31 Oct 2018 12:25

Verona Pharma Completes Enrollment In Clinical Trial Of RPL554

LONDON (Alliance News) - Verona Pharma PLC said Wednesday it has completed the enrollment for its Phase 2 clinical trial evaluating the effect of nebulised RPL554 as an add-on to dual therapy in a

Read more
26 Oct 2018 11:46

Verona Pharma turns in positive data from RPL554 trials

(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma turned in some positive data from its pre-clinical and Phase 2a trials on its potential cystic fibrosis treatment RPL554.

Read more
1 Aug 2018 12:49

Verona Pharma Starts Phase 2 Trial For Respiratory Disease Treatment

LONDON (Alliance News) - Verona Pharma PLC said Wednesday that it started the second phase of a clinical trial of its nebulized RPL554 drug for the treatment of patients with chronic obstructive 2

Read more
8 May 2018 07:01

LONDON MARKET EARLY CALL: Stocks Called Lower As Iran Fears Boost Oil

LONDON (Alliance News) - Stock prices in London are seen opening lower on Tuesday following Monday's UK bank holiday as Chinese exports recovered at a faster pace in April amid concerns the US

Read more
26 Mar 2018 10:19

Verona Pharma Shares Rise As It Gets Good Results From RPL554 Trials

LONDON (Alliance News) - Verona Pharma PLC said Monday it has received positive top-line data from its phase 2b study for its proposed RPL554 treatment.RPL554 is a for

Read more
8 Mar 2018 13:59

DIRECTOR DEALINGS: Verona Pharma CEO Karlsson Buys 3,250 Shares

LONDON (Alliance News) - Verona Pharma PLC, a clinical-stage biopharmaceutical company, said Thursday that Chief Executive Officer Jan-Anders Karlsson purchased 3,250 ordinary

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.